v3.26.1
Segment Information (Details)
 3 Months Ended
Mar. 31, 2026
USD ($)
segment
Mar. 31, 2025
USD ($)
Segment Reporting [Abstract]    
Number of operating segments | segment 1  
Revenue:    
Total revenue $ 152,455 $ 25,427
Cost of revenues 242,325 0
Indirect costs:    
Total research and development 660,462 2,297,381
Selling, general and administrative 2,248,566 2,309,164
Total operating expenses 2,909,028 4,606,545
Loss from operations (2,998,898) (4,581,118)
Other income, net (991) 202,811
Net loss (2,999,889) (4,378,307)
Reportable Segment    
Revenue:    
Total revenue 152,455 25,427
Cost of revenues 242,325 0
Direct program costs:    
Contra-R&D expenses (3,069,146) (2,618,373)
Total research and development direct program costs (129,398) 1,174,790
Indirect costs:    
Contra R&D expenses (431,848) (448,392)
Total research and development indirect costs 789,860 1,122,591
Total research and development 660,462 2,297,381
Selling, general and administrative 2,248,566 2,309,164
Total operating expenses 2,909,028 4,606,545
Loss from operations (2,998,898) (4,581,118)
Interest expense 199,394 134,050
Interest income (191,688) (156,621)
Other income, net 6,715 180,240
Net loss (2,999,889) (4,378,307)
Contra-R&D expenses 3,069,146 2,618,373
Reportable Segment | Research and development services and royalty revenue    
Revenue:    
Total revenue 152,455 25,427
Reportable Segment | Ovaprene    
Direct program costs:    
Direct program costs: 1,231,760 1,495,727
Contra-R&D expenses (1,000,000.0) (500,000)
Indirect costs:    
Contra-R&D expenses 1,000,000.0 500,000
Reportable Segment | Sildenafil Cream    
Direct program costs:    
Direct program costs: 67,791 211,389
Reportable Segment | Other advanced clinical stage programs    
Direct program costs:    
Direct program costs: 375,763 490,562
Contra-R&D expenses (400,000) (500,000)
Indirect costs:    
Contra-R&D expenses 400,000 500,000
Reportable Segment | Phase 1 and Phase 1-ready clinical stage programs    
Direct program costs:    
Direct program costs: 96,055 496,747
Contra-R&D expenses 0 (100,000)
Indirect costs:    
Contra-R&D expenses 0 100,000
Reportable Segment | Preclinical stage programs    
Direct program costs:    
Direct program costs: 1,168,379 1,098,738
Contra-R&D expenses (1,700,000) (1,600,000)
Indirect costs:    
Contra-R&D expenses 1,700,000 1,600,000
Reportable Segment | Personnel-related (including stock-based compensation)    
Indirect costs:    
Indirect costs: 1,192,862 1,492,248
Reportable Segment | Other indirect costs    
Indirect costs:    
Indirect costs: $ 28,846 $ 78,735